CD38 regulatory antibody

Abstract

To provide anti-CD38 antibodies that may be used in the treatment of cancer, particularly solid and hematological cancers.SOLUTION: Provided is an anti-CD38 antibody having a particular sequence, or antigen-binding fragment thereof, the anti-CD38 antibody or antigen-binding fragment thereof exhibiting antibody-dependent cell-mediated cytotoxicity (ADCC) activity against CD38+ target cells, exhibiting no complement dependent cytotoxicity (CDC) or reduced CDC activity against CD38+ target cells as compared to Daratumumab under the same or substantially the same conditions, and inducing immune effector cell activation.SELECTED DRAWING: Figure 20